KCNJ2 and small cell lung carcinoma: In SCLC, KCNJ2/Kir2.1 promotes growth and chemoresistance through interaction with multidrug resistance protein 1 (MRP1/ABCC1) and induces cell cycle arrest; this blocks drug-induced apoptotic effects [11,191].